To the Editor:The colorectal cancer(CRC)is the fourthmost common cause of cancer deaths in China that was treated as a public health threat,accounting for approximately 10%of all the cancer-caused mortalities each yea...To the Editor:The colorectal cancer(CRC)is the fourthmost common cause of cancer deaths in China that was treated as a public health threat,accounting for approximately 10%of all the cancer-caused mortalities each year.[1]It usually takes decades to develop from a polyp to full CRC,[2]which allows a time window for detecting precancerous lesions and taking early steps for preventions and treatments.展开更多
To the Editor:Incretin-based therapies for type 2 diabetes mellitus(T2DM)include incretin mimetics of glucagonlike peptide-1 receptor agonists(GLP-1 RAs)and incretin enhancers of dipeptidyl peptidase-4(DPP-4)inhibitor...To the Editor:Incretin-based therapies for type 2 diabetes mellitus(T2DM)include incretin mimetics of glucagonlike peptide-1 receptor agonists(GLP-1 RAs)and incretin enhancers of dipeptidyl peptidase-4(DPP-4)inhibitors.[1]With good hypoglycemic effects of incretin-based drugs that show no weight gain or hypoglycemia risk,these drugs are increasingly used in patients with T2DM.展开更多
基金supported by a grant from the National Natural Science Foundation of China(No.72074011)
文摘To the Editor:The colorectal cancer(CRC)is the fourthmost common cause of cancer deaths in China that was treated as a public health threat,accounting for approximately 10%of all the cancer-caused mortalities each year.[1]It usually takes decades to develop from a polyp to full CRC,[2]which allows a time window for detecting precancerous lesions and taking early steps for preventions and treatments.
基金National Natural Science Foundation of China(No.72074011)
文摘To the Editor:Incretin-based therapies for type 2 diabetes mellitus(T2DM)include incretin mimetics of glucagonlike peptide-1 receptor agonists(GLP-1 RAs)and incretin enhancers of dipeptidyl peptidase-4(DPP-4)inhibitors.[1]With good hypoglycemic effects of incretin-based drugs that show no weight gain or hypoglycemia risk,these drugs are increasingly used in patients with T2DM.
